Suppr超能文献

大肠杆菌中重组肽的经济有效生产。

Cost-effective production of recombinant peptides in Escherichia coli.

机构信息

Department of Chemical Sciences, University of Naples Federico II, 80126, Naples, Italy.

IRCCS SDN, 80143, Naples, Italy.

出版信息

N Biotechnol. 2019 Jul 25;51:39-48. doi: 10.1016/j.nbt.2019.02.004. Epub 2019 Feb 18.

Abstract

Among bioactive peptides, cationic antimicrobial peptides (AMPs), also referred to as host defence peptides (HDPs), are valuable tools to treat infections, being able to kill a wide variety of microbes directly and/or modulate host immunity. HDPs have great therapeutic potential against antibiotic-resistant bacteria, viruses and even parasites. However, high manufacturing costs have greatly limited their development as drugs, thus highlighting the need to develop novel and competitive production strategies. Here, a cost-effective procedure was established to produce the high amounts of peptides required for basic and clinical research. Firstly, a novel culture medium was designed, which was found to support significantly higher cell densities and recombinant expression levels of peptides under test compared to conventional media. The procedure has been also efficiently scaled up by using a 5 L fermenter, while the costs have been lowered significantly by developing a successful auto-induction strategy, which has been found to support higher yields of target constructs and cell biomass compared to conventional strategies based on expression induction by IPTG. Interestingly, it was estimated that by increasing production scale from 100 to 1000 mg/batch, unit costs decreased strongly from 253 to 42 €/mg. These costs appear highly competitive when compared to chemical synthesis strategies. Altogether, the data indicate that the strategy represents an important starting point for the future development of large-scale manufacture of HDPs.

摘要

在生物活性肽中,阳离子抗菌肽(AMPs),也称为宿主防御肽(HDPs),是治疗感染的有价值工具,能够直接杀死多种微生物和/或调节宿主免疫。HDPs 对抗生素耐药细菌、病毒甚至寄生虫具有巨大的治疗潜力。然而,高制造成本极大地限制了它们作为药物的发展,因此需要开发新的、有竞争力的生产策略。在这里,建立了一种具有成本效益的程序,以生产用于基础和临床研究所需的大量肽。首先,设计了一种新型培养基,与传统培养基相比,该培养基能够显著提高测试肽的细胞密度和重组表达水平。该工艺还通过使用 5L 发酵罐进行了高效放大,同时通过开发成功的自动诱导策略,显著降低了成本,与基于 IPTG 表达诱导的传统策略相比,该策略支持更高的目标构建体和细胞生物质产量。有趣的是,据估计,将生产规模从 100mg/批增加到 1000mg/批,单位成本从 253 欧元/毫克大幅降低到 42 欧元/毫克。与化学合成策略相比,这些成本具有很强的竞争力。总之,数据表明,该策略代表了未来大规模生产 HDP 的重要起点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验